Evidence map›Paper›PMID 29020677›Full record

ArticleBlood purification2017

The Nephrologist Has Great Potential to Have an Important Role in the Intensive Care Unit: Reply to the Letter to the Editor of David J.R. Morgan.

David J Askenazi, Sarah Faubel

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood purification, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

David J AskenaziDepartment of Pediatrics, Division of Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA.
Sarah Faubel

Funding

UAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4M
Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)R01DK103608 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI ASKENAZI, DAVID JOSEPH, GOLDSTEIN, STUART L · 2014 to 2019
$3.0M
Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury R01FD005092 · FDA · INNOVATIVE BIOTHERAPIES, INC. · PI GOLDSTEIN, STUART L, HUMES, H. DAVID · 2015 to 2018
$976k
UAB Center for Clinical and Translational Science (CCTS) KL2 ComponentKL2TR000166 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2012 to 2013
$554k
FDA HHS R01 FD005092NCATS NIH HHS KL2 TR000166NCATS NIH HHS UL1 TR001417NIDDK NIH HHS R01 DK103608
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Intensive Care UnitsNephrologists

Identifiers

PMID29020677
PMCPMC5828956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.